Parker Hannifin (PH) traded up 2.71 % during a 24 hours period ending at 10:08 PM Central Europe on Tuesday 27th. One Parker Hannifin stock can currently be bought for about USD 900.73 on popular exchanges. Current supply of Parker Hannifin stocks is 125.8 mn. Parker Hannifin has a current market capitalization of USD 111.8 bn and approximately USD 603.1 mn worth of Parker Hannifin was traded on exchanges in the last 24 hours. Since last month end, Parker Hannifin has traded -6.72 % down. Simple moving average of last 200 days is at USD 949.55. The highest price of past 52 weeks was recorded at USD 1,099.94 on 08/06/2026. 52 weeks low was at USD 755.1 on 11/05/2025.
Summary of the latest news for Parker Hannifin
Parker Hannifin Corp. continues to experience modest market activity amid a broadly positive U.S. equity environment. The company’s shares are trading within a range that reflects recent investor confidence, with incremental gains observed early in the trading session. Analysts note that Parker Hannifin’s performance aligns with broader sector trends, maintaining steady momentum without significant volatility. The firm’s valuation metrics appear stable, and its dividend policy remains consistent with market expectations. While the stock has not been among the most active or heavily traded in the index, it benefits from a steady demand base and solid financial fundamentals. Overall, Parker Hannifin Corp. demonstrates resilience in a market that continues to see incremental upward movement, reinforcing its position as a reliable investment within the industrial sector.
Here is how related stocks have performed in the past 24 hours:
Marathon Petroleum (MPC) traded up 2.94 % and now trades at USD 435.98. Marathon Petroleum has a market capitalisation of USD 131 bn. Marathon Petroleum has a current price to earnings ratio of 15.96. Marathon Petroleum Corp is positioned for a notable earnings uptick in the coming quarter, according to recent analyst commentary. Rising gasoline and diesel prices across the United States have lifted the refining sector, and Marathon is expected to deliver a stronger earnings report in early November. Market observers note that the company’s performance could prompt a broader rally among U.S. refiners, as similar gains are anticipated for peers Phillips 66 and Valero Energy. While Marathon’s share price has already risen considerably this year, its valuation relative to forward earnings remains attractive, suggesting that a positive earnings surprise could further lift the stock. The company’s financial outlook is therefore being viewed as a potential short‑term catalyst for investors seeking exposure to the refining industry.
Capital One (COF) traded up 0.5 % and now trades at USD 203.44. Current market capitalisation for Capital One is USD 122.7 bn. Current price/earnings ratio for Capital One is 12.3. Capital One Financial Corp has reported a steady performance in the latest quarter, with continued growth in its loan book and a stable asset‑quality profile. The company’s loan disbursements expanded modestly, while the overall portfolio grew, reflecting ongoing demand for its credit products. Interest income rose, supporting a healthy net interest margin that remains largely unchanged from the previous period. Operating expenses have increased, yet the cost‑to‑income ratio has remained under control, indicating efficient management of operating costs. Credit losses and provisions have been maintained at a manageable level, and the company’s provisioning coverage continues to provide a buffer against potential credit stress. Liquidity remains robust, with a healthy cash and liquidity buffer that supports future disbursement needs. The company’s governance framework, including active risk oversight and a diversified funding base, supports its continued operational resilience.
Bristol-myers Squibb (BMY) traded up 0.21 % and now trades at USD 61.55. Bristol-myers Squibb has a market capitalisation of USD 126.6 bn. Bristol-myers Squibb has a current price to earnings ratio of 13.57. Bristol‑Myers Squibb has announced interim results from a phase III trial of its bispecific antibody‑drug conjugate, izalontamab brengitecan, in patients with EGFR‑mutated non‑small‑cell lung cancer who have progressed after tyrosine‑kinase inhibitor therapy. The study, presented at ESMO 2026, shows a substantially longer median progression‑free survival and higher confirmed response rate compared with standard platinum‑based chemotherapy, while the safety profile remains manageable. Bristol‑Myers Squibb is advancing the agent under a collaboration with SystImmune, and the company has received breakthrough‑therapy designation from the U.S. Food and Drug Administration for this indication. The data suggest a potentially meaningful improvement in outcomes for patients with limited treatment options following progression on EGFR‑targeted therapy.
Altria (MO) traded down -0.93 % and now trades at USD 73.47. Altria has a market capitalisation of USD 123.9 bn. Current price/earnings ratio for Altria is 15.7.
Vertex (VRTX) traded down -1.23 % and now trades at USD 521.03. Vertex has a market capitalisation of USD 132.1 bn. Current price/earnings ratio for Vertex is 30.63. Vertex Pharmaceuticals Inc. has experienced a muted reaction in the market following mixed developments. The company’s shares remained largely flat, reflecting a cautious stance among investors amid broader sector volatility. Industry analysts note that while some pharmaceutical peers have benefited from recent regulatory approvals, Vertex’s recent earnings report did not significantly alter investor sentiment, leading to a steady but unremarkable trading performance. The company continues to focus on its pipeline of novel therapies, but market participants appear to be waiting for clearer evidence of commercial traction before making decisive moves. This restrained response underscores a broader trend of cautious valuation in the sector, as stakeholders weigh the balance between potential breakthroughs and the need for sustained revenue growth.
About Parker Hannifin
Parker-Hannifin Corporation is a U.S.-based industrial and aerospace systems designer and manufacturer with its main base located in Cleveland. The company specializes in creating diversified industrial and aviation systems, including motion-control and fluid systems and components for industrial markets, as well as flight control, hydraulic, fluid conveyance, thermal-management, pneumatic, and lubrication systems and components for aerospace markets. Parker-Hannifin Corp. operates globally, serving customers all around the world. You can find more information about their products and services on their website, www.parker.com , and they are listed on the New York Stock Exchange.